• Healthcare Capital & Connections Summit
    September 11 - 13, 2018
    Shanghai, China

    Register Now
  • English | Chinese (中文)

    2017 Summit

    The Healthcare Capital & Connections Summit was founded in 2014 to connect US and Chinese companies and investors. In 2017, attendees also included companies and investors from Canada, Europe and across Asia. The Summit provides opportunities to share cross-border best practices and make connections to facilitate deals.

    1. Agenda

      2017 Summit Agenda

      Day One: Tuesday, September 12, 2017

      13:00 – 17:00 Zhang Jiang Site Visit
      18:00 – 20:30 O’Melveny Welcome Reception


      Day Two: Wednesday, September 13, 2017

      09:00 – 09:15 Welcome and Opening Remarks
      • David Sabow, Head of Life Science, Client Funds & Products, Silicon Valley Bank
      • Chen Yu, Managing Partner, Vivo Capital
      09:15 – 10:00 China’s Healthcare Market – Impact of Recent Regulatory Changes
      This presentation will explore the regulatory, demographic, economic and intellectual property reforms that will shape China’s healthcare system through the rest of the 21st Century, as well as present a perspective on the potential winners and losers in this transition.
      Moderator: Qiang Li, Partner, DLA Piper
      • Ellen Jiang, President of Ramed Medical Technology Co.,Ltd
      • Lisa Haile PhD, Partner and Co-Chair, Global Life Sciences Sector, DLA Piper
      • Grace Xu, Vice President, The Sanpower Group
      • Vladimir Makatsaria, Group Chairman, Medical Devices, Johnson & Johnson
      • Chen Yu, Managing Partner, Vivo Capital
      10:00 – 10:45 The Emergence of China Biotech
      No longer just a big market for generics, China is at the very beginning of becoming a leader in Biotech innovation on a global scale. What role is China likely to play in the future and what are the implications for the global Biotech community.
      Moderator: Jielun Zhu, Head of Healthcare Investment Banking Asia, Jefferies
      • Dr. Scott Liu, President & CEO of Shanghai, Henlius Biotech Inc.
      • Ming Guo, PhD, Co-Founder, President & COO, Ascentage Pharma
      • Ke Geng, Partner, O’Melveny
      10:45 – 11:15 Strategic Priorities in China: View of Biopharma Companies
      Over this past year there have been a number of high-profile cross-border collaborations and licensing deals between the West and China in the biomedical sector. However, companies operating in China must also navigate a broad array of challenges. This panel will explore the opportunities and challenges of the biopharmaceutical market in China and discuss the different strategies companies employ to be successful in the world’s second largest economy.

      Moderator: Monica He, Director for International Affairs, BIO
      • Mike Dethick, Managing Director for R&D-Based Pharmaceutical Association Committee (RDPAC)
      • Donnie McGrath, Chief of Corporate Strategy and Business Development, Biohaven
      • Werner Cautreels, CEO, Selecta Biosciences
      11:15 – 12:00 Cross Border M & A/Licensing— The Current State of Affairs
      Increasingly Chinese corporates are actively investing, licensing and acquiring global life science & healthcare technologies. Hear from leading business development professionals on the process and the key contributors to success and failure.
      Moderator: Andy Clayton, Principal & Head of Asia Healthcare Investment Banking, Piper Jaffray
      • Sammy Jiang, Vice President of International Business & Strategy, Luye Pharma Group
      • Jason Zhang, Managing Director, International Investment and Business Development, Humanwell
      • Hongbo Lu, PhD MBA, Partner, Lilly Asia Ventures
      • William Wang, Executive President of MedTech Division, Fosun Pharma
      • Dr. James Zhang, Vice President, 3SBio and CEO, Sunshine Guojian Pharmaceutical
      12:00 – 13:00 Lunch hosted by Johnson & Johnson
      13:00 – 17:00 Company Presentations and 1 on 1 Meetings Hear presentations from some of the most innovative Chinese and International life science and healthcare entrepreneurs. Conduct 1 on 1 meetings with investors and strategics, organized via Meeting Mojo software platform.
      18:00 – 21:00 Dinner hosted by SPD Silicon Valley Bank
      Welcome address from Dave Jones, President of SPD Silicon Valley Bank & SVB Asia


      Day Three: Thursday, September 14, 2017

      09:00 – 09:30 The Impact of China’s Reimbursement Landscape on Medtech Growth
      The payment environment in China is rapidly evolving with caps on drug and device mark-ups, a downward trend in tender pricing and domestic procurement preferences. In addition, national payment reform is being considered alongside joint provincial procurement and DRG pilots. This panel will explore the impact of the evolving payment environment on China’s doctors and patients, as well as both domestic and international manufacturers.
      Moderator: Helen Chen, Managing Director, Head of China Life Sciences, L.E.K. Consulting
      • Helen Zhang, AdvaMed Member
      • Michael Chang, Managing Director, Vivo Ventures
      09:30 – 10:15 Currency Restrictions & Trade Policy—Impact on Cross Border Deals
      In an environment of volatile trade policy and pressure on economic growth it has become increasingly challenging to move capital out of China. What is driving this, what are the best practices in navigating the current climate and what will influence this in the future.
      Moderator: Christina Zhang, Partner in Charge – Shanghai, Cooley
      • Qiaolin Ren, Senior Director, Product Development, Aucta Pharmaceuticals
      • Fay Xing, Partner, 6 Dimensions Capital
      • James Lu, Partner, Cooley
      10:15 – 11:00 Accessing Investment Capital in China
      Chinese venture capital has become an increasingly prevalent source of capital for global life science and healthcare innovation. What are Chinese VCs looking for? How does this compare and contrast to Sandhill Road and what do global executives need to know in order to navigate this process successfully?
      Moderator: Lu Huang, Managing Director, Morningside
      • Don Xu, Lynx Financial
      • Ching Zhu, Managing Partner, 6 Dimensions Capital
      • Chelsea Zhang, Partner, Ping An Ventures
      • Dr. Karen Liu, Founding Partner, 3E Bioventures
      11:00 – 11:45 Working with China A-Share Listed Companies
      China's A-share companies are increasingly looking overseas for partnerships, investments, and acquisition opportunities. We will discuss what is driving this interest, what they are looking for, the various options to work together, the evolving Chinese regulatory environment, the challenges/pitfalls and successful stories to overcome them, and the forecast for the future.
      Moderator Irene Hong, CEC Capital
      • Eric Tang, CEO, Nanjing King Friend Biotech
      • Alvin Syh, ‎General Manager at Buchang Asset Management Center
      • Wei Li, Director of Business Development, KPC Pharmaceuticals
      • Jingqun Yin, Vice President, Kanghong Pharmaceutical
      • Randy Xianpei Jia, Investment Director, Tianjin Chase Sun Pharmaceutical Co., Ltd.
      11:45 – 12:45 Lunch hosted by Piper Jaffray
      12:45 – 13:15 Medical Devices: The Global State of the Sector
      The importance of Medical Device interventions continues to increase as the global healthcare community seeks alternatives to a lifetime of costly therapies. Despite challenges created by continued consolidation and a more constrained US venture capital environment, innovation in the sector continues to thrive and the environment is ripe for creative cross-border transactions.
      Speaker Matt Steere, Managing Director, Life Sciences Investment Banking, Canaccord Genuity
      13:15 – 13:45 Next Frontiers of Global Innovation: Ophthalmology Futures
      Hosted by Ophthalmology Futures European and Asian Forums and kindly supported by the Santen Pharmaceutical (China) Co Ltd with the assistance of Carl Zeiss Meditec Inc, this panel will explore the diverse world of ophthalmic innovation and the immense investment and business opportunities that it offers. Ophthalmology involves the highest level of biotechnology and device technology miniaturized to a small and unique organ. For the savvy investor, for businesses inside and outside China who are interested in the vast market and development capability that this country can offer, ophthalmology promises to be a rapidly expanding and rewarding area.

      Moderator: Keith Barton, Consultant Ophthalmologist, Moorfields Eye Hospital, UK
      • Lu Lu, Divisional Head, Medical Development Division, Santen
      • Dr Chelvin Sng, Consultant, National University Hospital Singapore
      • Paul Hallen, Global Head, Surgical Retina and Glaucoma, Alcon
      • Joe Redner, Head of APAC Sales/Ophthalmic Devices, Medical Technology Business Group, ZEISS
      13:45 – 16:45 Company Presentations and 1 on 1 Meetings
      Hear presentations from some of the most innovative Chinese and international life science and healthcare entrepreneurs. Conduct 1 on 1 meetings with investors and strategics, organized via Meeting Mojo software platform.
    2. 2017 Presenters

      Company Presenters

      Abaxis Asia Limited

      Advanced Accelerator Applications

      Allurion Technologies

      Arterys Inc.

      BAROnova, inc.

      Biohaven Pharmaceuticals

      BuChang Asset Management

      Cantabio Pharmaceuticals

      Connect Biopharma

      Cynvenio Biosystems, Inc.

      EOC Pharma

      Health 100

      Histogenics Corporation

      Impulse Dynamics

      Innara Health

      Inovio Pharmaceuticals

      Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd.


      Recursion Pharmaceuticals

      Selecta Biosciences

      Seven Bridges Geonomics

      Stealth BioTherapeutics Inc.

      Surgical Specialties Corproration, China Division

      Symic Bio

      Tianjin Chase Sun Pharmaceutical Co., Ltd

      Tizona Therapeutics, Inc.

      TOMA Biosciences, Inc.

      Ultivue Inc.

      Verge Genomics

      Wallaby Medical

      Xcell Biosciences


    3. Attendees


      3E Bioventures
      3S Bio
      6 Dimensions Capital
      Abaxis Asia Limited
      Advanced Accelerator Applications
      Allurion Technologies
      Aurinia Pharmaceuticals Inc.
      BIO (Biotechnology Innovation Organization)
      Canaccord Genuity
      China MedConnect
      Cohera Medical
      Connect Biopharma
      Cooley LLP
      Cynvenio Biosystems, Inc.
      DLA Piper LLP
      Dornier MedTech
      Fenwick & West LLP
      Fresco Capital
      Histogenics Corporation
      Humanwell Healthcare Group
      Impulse Dynamics
      Innara Health
      International Co-Innovation Center for Advanced Medical Technology
      Johnson & Johnson
      Lumira Capital


      Lynx Financial
      M. H. Carnegie & Co.
      Morningside Ventures
      National University Hospital
      Nuance Biotech
      O'Melveny & Myers LLP
      Ophthalmology Futures Forums
      Permira Advisers LLP
      Ping An Ventures
      Piper Jaffray
      Radius Health
      Ramed (Beijing) Medical Technology Co.,Ltd
      Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Co.,Ltd.
      Silicon Valley Bank
      Sonendo, Inc.
      SPD Silicon Valley Bank
      Spring Bank Pharmaceuticals
      Silicon Valley Bank
      SPD Silicon Valley Bank
      SVB Asia Link
      SVB BP Beijing Co. Ltd
      Symic Bio
      Tianjin Chase Sun Pharmaceutical Co.
      TOMA Biosciences, Inc.
      Ultivue Inc.
      Vivo Capital
      Xcell Biosciences
      Yuyue Medical

  • Platinum Sponsors


  • The presenters at Healthcare Capital & Connections Summit are independent third parties and are not affiliated with SVB Financial Group. See Terms of Use for more detail.

    © 2018 SVB Financial Group. All rights reserved. SVB, SVB FINANCIAL GROUP, SILICON VALLEY BANK, MAKE NEXT HAPPEN NOW and the chevron device are trademarks of SVB Financial Group, used under license. Silicon Valley Bank is a member of the FDIC and the Federal Reserve System. Silicon Valley Bank is the California bank subsidiary of SVB Financial Group (Nasdaq: SIVB).